Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study

Brain

Volumn 136, Issue 9, 2013, Pages 2707-2716

  Hooshmand, Babak ^a,b   Polvikoski, Tuomo ^c   Kivipelto, Miia ^a,b,d   Tanskanen, Maarit ^e   Myllykangas, Liisa ^e   Erkinjuntti, Timo ^f   Mäkelä, Mira ^f   Oinas, Minna ^f   Paetau, Anders ^f   Scheltens, Philip ^g   Van Straaten, Elizabeth C W ^g   Sulkava, Raimo ^d   Solomon, Alina ^a,b,d  

^a AGING RESEARCH CENTER   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer pathology; Alzheimer's disease; cerebrovascular pathology; elderly; homocysteine

Indexed keywords

ALPHA SYNUCLEIN; HOMOCYSTEINE;

AGED; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; ARTICLE; AUTOPSY; BRAIN INFARCTION; FEMALE; HEMISPHERE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; TEMPORAL LOBE; TIME OF DEATH; WHITE MATTER;

EID: 84883376001     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt206     Document Type: Article

References (55)

1. Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 2010; 75: 1195-202.
2. Alexopoulos P, Gunther F, Popp J, Jessen F, Peters O, Wolf S, et al. Plasma homocysteine and cerebrospinal fluid neurodegeneration biomarkers in mild cognitive impairment and dementia. J Am Geriatr Soc 2009; 57: 737-9.
3. Allen LH. How common is vitamin B-12 deficiency? Am J Clin Nutr 2009; 89: 693S-6.
4. Allsop D, Haga SI, Haga C, Ikeda SI, Mann DM, Ishii T. Early senile plaques in Down's syndrome brains show a close relationship with cell bodies of neurons. Neuropathol Appl Neurobiol 1989; 15: 531-42.
5. Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2000; 15: 911-6.
6. Barkhof F, Polvikoski TM, van Straaten EC, Kalaria RN, Sulkava R, Aronen HJ, et al. The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology 2007; 69: 1521-7.
7. Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol 2012; 72: 599-609.
8. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
9. Chai GS, Jiang X, Ni ZF, Ma ZW, Xie AJ, Cheng XS, et al. Betaine attenuates Alzheimer-like pathological changes and memory deficits induced by homocysteine. J Neurochem 2013; 124: 388-96.
10. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998; 55: 1449-55.
11. Coppieters N, Dragunow M. Epigenetics in Alzheimer's disease: a focus on DNA modifications. Curr Pharm Des 2011; 17: 3398-412.
12. den Heijer T, Vermeer SE, Clarke R, Oudkerk M, Koudstaal PJ, Hofman A, et al. Homocysteine and brain atrophy on MRI of nondemented elderly. Brain 2003; 126 (Pt 1): 170-5.
13. Doets EL, van Wijngaarden JP, Szczecinska A, Dullemeijer C, Souverein OW, Dhonukshe-Rutten RA, et al. Vitamin B12 intake and status and cognitive function in elderly people. Epidemiol Rev 2013; 35: 2-21.
14. Fazekas F, Kapeller P, Schmidt R, Offenbacher H, Payer F, Fazekas G. The relation of cerebral magnetic resonance signal hyperintensities to Alzheimer's disease. J Neurol Sci 1996; 142: 121-5.
15. Flicker L, Martins RN, Thomas J, Acres J, Taddei K, Norman P, et al. Homocysteine, Alzheimer genes and proteins, and measures of cognition and depression in older men. J Alzheimers Dis 2004; 6: 329-36.
16. Ford AH, Almeida OP. Effect of homocysteine lowering treatment on cognitive function: a systematic review and meta-analysis of randomized controlled trials. J Alzheimers Dis 2012; 29: 133-49.
17. Harris J, Chimelli L, Ray D. Chapter 10: Nutritional deficiencies, metabolic disorders and toxins affecting the nervous system. In: Love S, Louis DN, Ellison DW, editors. Greenfield's neuropathology. 8th edn. London: Hodder Arnold; 2008. p. 679-81.
18. Hasegawa T, Ukai W, Jo DG, Xu X, Mattson MP, Nakagawa M, et al. Homocysteic acid induces intraneuronal accumulation of neurotoxic Abeta42: implications for the pathogenesis of Alzheimer's disease. J Neurosci Res 2005; 80: 869-76.
19. Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith AD. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol 2002; 59: 787-93.
20. Hooshmand B, Solomon A, Kareholt I, Leiviska J, Rusanen M, Ahtiluoto S, et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology 2010; 75: 1408-14.
21. Hooshmand B, Solomon A, Kareholt I, Rusanen M, Hanninen T, Leiviska J, et al. Associations between serum homocysteine, holotranscobalamin, folate and cognition in the elderly: a longitudinal study. J Intern Med 2012; 271: 204-12.
22. Irizarry MC, Gurol ME, Raju S, Diaz-Arrastia R, Locascio JJ, Tennis M, et al. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology 2005; 65: 1402-8.
23. Jochemsen HM, Kloppenborg RP, de Groot LC, Kampman E, Mali WP, van der Graaf Y, et al. Homocysteine, progression of ventricular enlargement, and cognitive decline: the Second Manifestations of ARTerial disease-Magnetic Resonance study. Alzheimers Dement 2013; 9: 302-9.
24. Luchsinger JA, Tang MX, Miller J, Green R, Mehta PD, Mayeux R. Relation of plasma homocysteine to plasma amyloid beta levels. Neurochem Res 2007; 32: 775-81.
25. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-24.
26. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-86.
27. Myllykangas L, Polvikoski T, Reunanen K, Wavrant-De Vrieze F, Ellis C, Hernandez D, et al. ApoE epsilon3-haplotype modulates Alzheimer beta-amyloid deposition in the brain. Am J Med Genet 2002; 114: 288-91.
28. Myllykangas L, Polvikoski T, Sulkava R, Verkkoniemi A, Crook R, Tienari PJ, et al. Genetic association of alpha2-macroglobulin with Alzheimer's disease in a Finnish elderly population. Ann Neurol 1999; 46: 382-90.
29. Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 2006; 580: 2994-3005.
30. Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, et al. Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem 2007; 53: 1129-36.
31. Oinas M, Polvikoski T, Sulkava R, Myllykangas L, Juva K, Notkola IL, et al. Neuropathologic findings of dementia with lewy bodies (DLB) in a population-based Vantaa 85 + study. J Alzheimers Dis 2009; 18: 677-89.
32. Outinen PA, Sood SK, Pfeifer SI, Pamidi S, Podor TJ, Li J, et al. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood 1999; 94: 959-67.
33. Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995; 333: 1242-7.
34. Polvikoski TM, van Straaten EC, Barkhof F, Sulkava R, Aronen HJ, Niinisto L, et al. Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology 2010; 75: 2071-8.
35. Popp J, Lewczuk P, Linnebank M, Cvetanovska G, Smulders Y, Kolsch H, et al. Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease. J Alzheimers Dis 2009; 18: 819-28.
36. Rastas S, Pirttila T, Mattila K, Verkkoniemi A, Juva K, Niinisto L, et al. Vascular risk factors and dementia in the general population aged 485 years: prospective population-based study. Neurobiol Aging 2010; 31: 1-7.
37. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004; 50: 3-32.
38. Sachdev P, Parslow R, Salonikas C, Lux O, Wen W, Kumar R, et al. Homocysteine and the brain in midadult life: evidence for an increased risk of leukoaraiosis in men. Arch Neurol 2004; 61: 1369-76.
39. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med 2009; 360: 2302-9.
40. Scarpa S, Fuso A, D'Anselmi F, Cavallaro RA. Presenilin 1 gene silencing by S-adenosylmethionine: a treatment for Alzheimer disease? FEBS Lett 2003; 541: 145-8.
41. Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Vermersch P, et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993; 114: 7-12.
42. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in probable Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992; 55: 967-72.
43. Schmidt R, Schmidt H, Haybaeck J, Loitfelder M, Weis S, Cavalieri M, et al. Heterogeneity in age-related white matter changes. Acta Neuropathol 2011; 122: 171-85.
44. Seshadri S. Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer's disease? J Alzheimers Dis 2006; 9: 393-8.
45. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-83.
46. Seshadri S, Wolf PA, Beiser AS, Selhub J, Au R, Jacques PF, et al. Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol 2008; 65: 642-9.
47. Smach MA, Jacob N, Golmard JL, Charfeddine B, Lammouchi T, Ben Othman L, et al. Folate and homocysteine in the cerebrospinal fluid of patients with Alzheimer's disease or dementia: a case control study. Eur Neurol 2011; 65: 270-8.
48. Smith AD. The worldwide challenge of the dementias: a role for B vitamins and homocysteine? Food Nutr Bull 2008; 29 (Suppl 2): S143-72.
49. Sontag E, Nunbhakdi-Craig V, Sontag JM, Diaz-Arrastia R, Ogris E, Dayal S, et al. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci 2007; 27: 2751-9.
50. Tanskanen M, Makela M, Myllykangas L, Notkola IL, Polvikoski T, Sulkava R, et al. Prevalence and severity of cerebral amyloid angiopathy: a population-based study on very elderly Finns (Vantaa 85 + ). Neuropathol Appl Neurobiol 2012a; 38: 329-36.
51. Tanskanen M, Makela M, Myllykangas L, Rastas S, Sulkava R, Paetau A. Intracerebral hemorrhage in the oldest old: a population-based study (vantaa 85 + ). Front Neurol 2012b; 3: 103.
52. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan Study. Ann Neurol 2002; 51: 285-9.
53. Yamaguchi H, Haga C, Hirai S, Nakazato Y, Kosaka K. Distinctive, rapid, and easy labeling of diffuse plaques in the Alzheimer brains by a new methenamine silver stain. Acta Neuropathol 1990; 79: 569-72.
54. Yamamoto T, Hirano A. A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer's neurofibrillary tangles. Neuropathol Appl Neurobiol 1986; 12: 3-9.
55. Zhang CE, Tian Q, Wei W, Peng JH, Liu GP, Zhou XW, et al. Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol Aging 2008; 29: 1654-65.